| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2024072 | Seminars in Cancer Biology | 2008 | 8 Pages |
Abstract
Growing evidence supports the notion that pharmaceutical targeting of the 5-hydroxytryptamine (5-HT) and dopamine (DA) systems offers the potential to treat human immune system disorders. This review describes this emerging area of research, which has the benefit of being supported by a relatively detailed understanding of these monoamine systems within other tissues of the body. Furthermore, the availability of a number of pharmaceutical agents originally developed to manipulate central monoamine function, offer many suitable drug candidates to test their therapeutic potential in the immune pathology arena.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Nicholas M. Barnes, John Gordon,